Literature DB >> 18230340

Tuberous sclerosis complex 2 loss-of-function mutation regulates reactive oxygen species production through Rac1 activation.

Tsukasa Suzuki1, Swadesh K Das, Hirohumi Inoue, Machiko Kazami, Okio Hino, Toshiyuki Kobayashi, Raymond S Yeung, Ken-Ichi Kobayashi, Tadahiro Tadokoro, Yuji Yamamoto.   

Abstract

The products of the TSC1 (hamartin) and TCS2 (tuberin) tumor suppressor genes negatively regulate cell growth by inhibiting mTOR signaling. Recent research has led to the postulation that tuberin and/or hamartin are involved in tumor migration, presumably through Rho activation. Here we show that LEF-8 cells, which contain a Y1571 missense mutation in tuberin, express higher Rac1 activity than tuberin negative and positive cells. We also provide evidence of obvious lamellipodia formation in LEF-8 cells. Since the production of TSC2(Y1571H) cannot form a hetero-complex with hamartin, we further analyzed another mutant, TSC2(R611Q), which also lacks the ability to form a complex with hamartin. Introducing both forms of mutated TSC2 into COS-1 cells increased Rac1 activity as well as cell motility. We also found these two mutants interacted with Rac1. We further demonstrated that the introduction of mutated TSC2 into COS-1 cells can generate higher reactive oxygen species (ROS). These results indicate that loss-of-function mutated tuberin can activate Rac1 and thereby increase ROS production.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230340     DOI: 10.1016/j.bbrc.2008.01.077

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.

Authors:  Doug Medvetz; Yang Sun; Chenggang Li; Damir Khabibullin; Murugabaskar Balan; Andrey Parkhitko; Carmen Priolo; John M Asara; Soumitro Pal; Jane Yu; Elizabeth P Henske
Journal:  Mol Cancer Res       Date:  2014-09-03       Impact factor: 5.852

2.  Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration.

Authors:  R Michelle Reith; Sharon Way; James McKenna; Katherine Haines; Michael J Gambello
Journal:  Neurobiol Dis       Date:  2011-03-17       Impact factor: 5.996

3.  ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS.

Authors:  Angela Alexander; Sheng-Li Cai; Jinhee Kim; Adrian Nanez; Mustafa Sahin; Kirsteen H MacLean; Ken Inoki; Kun-Liang Guan; Jianjun Shen; Maria D Person; Donna Kusewitt; Gordon B Mills; Michael B Kastan; Cheryl Lyn Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

4.  TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species.

Authors:  Chong Chen; Yu Liu; Runhua Liu; Tsuneo Ikenoue; Kun-Liang Guan; Yang Liu; Pan Zheng
Journal:  J Exp Med       Date:  2008-09-22       Impact factor: 14.307

5.  Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.

Authors:  Matthildi Valianou; Andrew M Cox; Benjamin Pichette; Shannon Hartley; Unmesha Roy Paladhi; Aristotelis Astrinidis
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Tuberin regulates reactive oxygen species in renal proximal cells, kidney from rodents, and kidney from patients with tuberous sclerosis complex.

Authors:  Samy L Habib; Hanna E Abboud
Journal:  Cancer Sci       Date:  2016-07-25       Impact factor: 6.716

7.  Stability of tuberous sclerosis complex 2 is controlled by methylation at R1457 and R1459.

Authors:  Seishu Gen; Yu Matsumoto; Ken-Ichi Kobayashi; Tsukasa Suzuki; Jun Inoue; Yuji Yamamoto
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

8.  DOCK5 regulates energy balance and hepatic insulin sensitivity by targeting mTORC1 signaling.

Authors:  Yerui Lai; Anjiang Zhao; Minghong Tan; Mengliu Yang; Yao Lin; Shengbing Li; Jinlin Song; Hongting Zheng; Zhiming Zhu; Dongfang Liu; Chaohong Liu; Ling Li; Gangyi Yang
Journal:  EMBO Rep       Date:  2019-12-29       Impact factor: 8.807

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.